Interferon-Beta-1a (Rebif) a Risk Factor on Liver, Kidney and Sex Hormones with Multiple Sclerosis Patients: A Review
Downloads
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (C.N.S). It is an autoimmune degenerative disease characterized by damage to the insulating myelin sheath covering the axons of the brain and spinal cord, often leading to a state of disability. The management of MS remains a major challenge.
Interferon beta (IFN-β) is one of the most important licensed treatments for disease-modifying MS. interferon acts as an immunomodulation by reducing antigen presentation and T - cells. enhancing suppressor reducing pro - inflammatory cytokines, and Lymphocyte suppression migration in CNS. I.FN-β is a relatively effective Freedom of choice. Medication for patients with M.S. However, this treatment has multiple side effects, Including reactions at the injection site liver, dysfunction, decreased peripheral blood cell counts, and worsening depression. Its immunological characteristics and the genetic diversity of patients are associated with variability in response. Current review will discuss the various said effectes of interferon beta (IFN-β) at liver, kidney function at multiple sclerosis patients. The review focuses on the extent to which interferon (IFN-I) damages liver and kidney tissue, directly impacting the biology and function of many types of diseases. of kidney and liver cells. It also discusses the extent to which male and female sex hormone levels are affected, especially during pregnancy in women with MS are treatment by interferon repeatedly weekly for long periods.
Conclusion: The review concluded that long-term and repeated interferon therapy has significant effects on patients with multiple sclerosis, especially on liver and kidney tissues, as well as on fetuses in pregnant women, especially in the last stages of pregnancy, which requires multiple studies to ensure the safety of multiple sclerosis patients, especially in women during pregnancy.
Recommendations: The review recommends further research studies on changing the doses of interferon and adding some pharmaceutical compounds accompanying the use of interferon to reduce its potential effects on liver and kidney cells and sex hormone levels in M.S.patients.
Kappos L, O’Connor PW, Polman CH, et al. Clinical effects of natali-zumab on multiple sclerosis appear early in treatment course. J Neurol.2013;260:1388–95.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765–79.
Minden, S.L, Marder, W.D., Harrold, L N. and Dor, A. (1993). Multiple Sclerosis: a statistical portrait. A compendium of data on demographics, disability, and health services utilization in the United States. Cambridge, MA: A b t Associates.
Pugliatti, M., Sotgiu, S. and Rosati, G. (2002). The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 10A, 182-191.
Marisa P. McGinley, DO ; Carolyn H. Goldschmidt, DO ; Alexander D. Rae-Grant, MD. Diagnosis and Treatment of Multiple SclerosisA Review Affiliations.JAMA. 2021;325(8):765-779. doi:10.1001/jama.2020.26858
McGinley M, Goldschmidt Ch, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis. A review. JAMA 325:765–779
Comi G, Radaelli M, Soelberg P et al (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389(10076):1347–1356
J U Gutterman. Cytokine therapeutics: Lessons from interferon a Proc Natl Acad Sci USA 91, 1198–1205 (1994). roc. Nadl. Acad. Sci. USA Vol. 91, pp. 1198-1205, February 1994
E DeMaeyer, G Galasso, H Schellekens The Biology of the Interferon System (Elsevier/North–Holland Biomedical, Amsterdam, 1981).
S R Sprang, J F Bazan. Cytokine structur okine structural taxonomy and mechanisms of r onomy and mechanisms of receptor engagement Curr Opin Struct Biol 3, 815–827 (1993).
Mark S. Freedman. Patricia K. Coyle. Kerstin Hellwig. Barry Singer. Daniel Wynn. Bianca Weinstock-Guttman. Silva Markovic-Plese. Andrew Galazka. Fernando Dangond. Julie Korich. Anthony T. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives Rede Neurol Ther (2024) 13:283–322 https://doi.org/10.1007/s40120-023-00565-7
Multiple sclerosis: time for early treatment with high efcacy drugs Krzysztof Selmaj, Bruce A. C. Cree. Michael Barnett Alan Thompson • Hans Peter Hartung Journal of Neurology (2024) 271:105–115 https://doi.org/10.1007/s00415-023-11969-8
Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010; 74(Suppl 1):S17-S24.
Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.Neurology 2010; 74(Suppl 1): S25-S30.
Pozzilli C, Koudriavtseva T. Interferon beta 1a. Baillieres Clin Neurol 1997; 6(3): 481-93.
Arnon R, Aharoni R. Glatiramer acetate From bench to bed and back. Isr Med Assoc J 2019; 21(3): 151-7.
Walther EU, Hohlfeld R. Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology 1999; 53(8): 1622-7.
Isaacs A, Lindenmann J. Virus interference I, the interferon. Proc Royal Soc B.1957;147:258–267. PubMed: 13465720.
Dorr RT. Interferon-alpha in malignant and viral diseases. A review. Drugs. 1993;45(2):177–211. PubMed: 7681371. doi: 10.2165/00003495-199345020-00003
Jacobs L, O’Malley J, Freeman A, et al. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 1981;214(4524):1026–1028. PubMed: 4026626. doi: 10.1126/science.6171035
Rizzo F, Giacomini E, Mechelli R, et al. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol. 2016;94(9):886–894. PubMed: 27265253. doi: 10.1038/icb.2016.55
Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple clerosis. Neurology. 2010;74(Suppl 1):S17–S24. PubMed: 20038758. doi:10.1212/WNL.0b013e3181c97d99
Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine [ PubMed: 28261400]. 2017;16:41–50. doi: 10.1016/j.ebiom.2017.01.042
Feng X, Bao R, Li L, et al. Interferon-β corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019;49:269–283. PubMed: 31648992. doi: 10.1016/j.ebiom.2019.09.059
Impact of Early Interferon Beta1b Treatment on Disease Evolution Over 5Years in Patients with a First Event Suggestive of Multiple Sclerosis
LiverTox: Clinical and Research Information on Drug Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Beta Interferon. [Updated 2018 May 4].Bookshelf URL: https://www.ncbi.nlm.nih.gov/books
Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M. Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. Dig Dis Sci 2013; 58: 1766-75. PubMed Citation
Nicola Salvatore Orefice, , Olga Ferraro2, Francesco Barbato, Antonio Carotenuto, Roberta Lanzillo Vincenzo Brescia Morra2, Giovanni Coppola2, Giuseppe Orefice2 Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature Pharmacology & Pharmacy, 2012, 3, 248-253 http://dx.doi.org/10.4236/pp.2012.32033 Published Online April 2012 (http://www.SciRP.org/journal/pp)
Christopher V, Scolding N, Przemioslo RT. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis. J Neurol 2005; 252(7): 855-6.
Kozielewicz D, Pawlowska M. Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. Neurol Neurochir Pol 2015; 49(6): 451-5.
Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002; 97(3): 767-8.
Yamaguchi H, Sakai K, Goto Y, Yamada M. Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis. J Neurol 2018; 265(6): 1469-71.
Mishra A, Guindi M, Kandel G, Streutker CJ. Autoimmune hepatitis-like reaction developing in a patient treated with interferon-beta1a. Histopathology 2015; 66(4): 605-7.
Liao MF, Yen SC, Chun-Yen L, Rong-Kuo L. Delayed Liver Function Impairment Secondary to Interferon beta-1a Use in Multiple Sclerosis. Case Rep Neurol 2013; 5(2): 130-4.
Byrnes V, Afdhal N, Challies T, Greenstein PE. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis. Ann Hepatol 2006; 5(1): 56-9.
Pietrosi G, Mandala L, Vizzini GB, Gruttadauria S, Minervini MI, Burgio G, et al. Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta 1a: A fatal combination? Transpl Int 2008;21(5): 502-4.
Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001; 56(10): 1416.
Neumann H, Csepregi A, Sailer M, Malfertheiner P. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. J Neurol 2007; 254(6): 816-7.
Francis GS, Kaplowitz N, Alteri E. Liver injury associated with the beta-interferons for MS. Neurology 2004; 63(6): 1142-3.
Grieco A, Montalto M, Vero V, Maria VF, Gasbarrini G. Severe acute hepatitis after resumption of interferon-Beta therapy for multiple sclerosis: A word of caution. Am J Gastroenterol 2007; 102(11): 2606-7.
Kowalec K, Yoshida EM, Traboulsee A, Carleton B, Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord 2013; 2(1): 57-9.
Pulicken M, Koteish A, DeBusk K, Calabresi PA. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006; 66(12): 1954-5.
Gordon S Francis 1, Yves Grumser, Enrica Alteri, Alain Micaleff, Fanny O'Brien, Jonathan Alsop, Margaretha Stam Moraga, Neil Kaplowitz2003;26(11):815-27. doi: 10.2165/00002018-200326110-00006.Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. 2004;27(10):745-56.
Lorenzo Lodi 1, Maria V Mastrolia 2, Federica Bello 3, Giovanni M Rossi 4, Maria L Angelotti 5, Yanick J Crow 6, Paola Romagnani 7, Augusto Vaglio Type I interferon-related kidney disorders Areviw.2022 Jun;101(6):1142-1159. doi: 10.1016/j.kint.2022.02.031. Epub 2022 Mar 24
Hansen T, New D, Reeve R, Donne R, Stephens W. Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: Case report and review of the literature. NDT Plus 2009; 2(6): 466-8.
Tornes L, Delgado S, Garcia-Buitrago M Ortega MR, Rammohan KW. Focal segmental glomerulosclerosis secondary to subcutaneous interferon beta-1a treatment in a patient with multiple sclerosis. Mult Scler Relat Disord 2012; 1(3): 148-51.
Ozturk M, Basoglu F, Yilmaz M, Ozagari AA, Baybas S. Interferon beta associated nephropathy in a Multiple Sclerosis patient: A case and review. Mult Scler Relat Disord 2016; 9: 50-3.
Evans R, Rudd P, Bass P, Harber M. Tip variant focal segmental glomerulosclerosis associated with interferon-beta treatment of multiple sclerosis. BMJ Case Rep 2014; 2014: bcr2013203077.
Capobianco M, Piccoli G, Neve Vigotti F, Scapoli P, Deagostini MC, Albera C, et al. Interferon beta-related nephropathy and interstitial lung disease: A new association and a long-term warning. Mult Scler 2014;20(7): 889-91.
Yuste C, Rapalai M, Pritchard BA, Jones TJ, Tucker B, Ramakrishna SB. Nephrotic-range proteinuria on interferon-beta treatment: Immune-induced glomerulonephritis or other pathway? Clin Kidney J 2014; 7(2): 190-3.
Gucev ZS, Kirovski I, Jancevska A, Popjordanova N, Tasic V. Papillorenal syndrome after Beta-interferon treatment in pregnancy. Ren Fail 2009; 31(7): 602-5.
Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther 2013; 7: 723-8.
Li CG, Bono L, Tortorici C, Giammarresi C, Rotolo U. Renal thrombotic microangiopathy induced by beta-interferon. NDT Plus 2011; 4(1): 80.
Auty A, Saleh A. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci 2005; 32(3): 366-8.
J.M. Greer et al.Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controlsJ. Autoimmun. (2004)
I.F. Cook.Sexual dimorphism of humoral immunity with human vaccines Vaccine (2008) •M. Debouverie Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France, J. Neurol. Sci.(2009)
G.C. Ebers et al.Parent-of-origin effect in multiple sclerosis: observations in half-siblings Lancet(2004)
M.J. Eikelenboom et al.Gender differences in multiple sclerosis: Cytokines and vitamin DJ. Neurol. Sci.(2009)
Bove, R.; Musallam, A.; Healy, B.C.; Raghavan, K.; Glanz, B.I.; Bakshi, R.; Weiner, H.; De Jager, P.L.; Miller, K.K.; Chitnis, T. Low Testosterone Is Associated with Disability in Men with Multiple Sclerosis. Mult. Scler. 2014, 20, 1584–1592..
Sicotte, N.L.; Giesser, B.S.; Tandon, V.; Klutch, R.; Steiner, B.; Drain, A.E.; Shattuck, D.W.; Hull, L.; Wang, H.-J.; Elashoff, R.M.; et al. Testosterone Treatment in Multiple Sclerosis: A Pilot Study. Arch. Neurol. 2007, 64, 683–688..
Kurth, F.; Luders, E.; Sicotte, N.L.; Gaser, C.; Giesser, B.S.; Swerdloff, R.S.; Montag, M.J.; Voskuhl, R.R.; Mackenzie-Graham, A. Neuroprotective Effects of Testosterone Treatment in Men with Multiple Sclerosis. Neuroimage Clin. 2014, 4, 454–460..
Gold, S.M.; Chalifoux, S.; Giesser, B.S.; Voskuhl, R.R. Immune Modulation and Increased Neurotrophic Factor Production in Multiple Sclerosis Patients Treated with Testosterone. J. Neuroinflammation 2008, 5, 32..
Federica.Murgia, Florianna Giagnoni, Lorena Lorefice, Paola Caria, Tinuccia Dettori, Maurizio N. D’Alterio, , Stefano Angioni, Aran J. Hendren, Pierluigi Caboni, Monica Pibiri, Giovanni Monni, Eleonora Cocco and Luigi Atzori Sex Hormones as Key Modulators of the Immune Response in Multiple Sclerosis: A Review Biomedicines 2022, 10, 3107. https://doi.org/10.3390/biomedicines10123107
Bove, R.; Chitnis, T. The Role of Gender and Sex Hormones in Determining the Onset and Outcome of Multiple Sclerosis. Mult. Scler. 2014, 20, 520–526..
Voskuhl, R.R.; Gold, S.M. Sex-Related Factors in Multiple Sclerosis Susceptibility and Progression. Nat. Rev. Neurol. 2012, 8, 255–263..
Ysrraelit, M.C.; Correale, J. Impact of Sex Hormones on Immune Function and Multiple Sclerosis Development. Immunology 2019, 156, 9–22..
Pozzilli, C.; Tomassini, V.; Marinelli, F.; Paolillo, A.; Gasperini, C.; Bastianello, S. “Gender Gap” in Multiple Sclerosis: Magnetic Resonance Imaging Evidence. Eur. J. Neurol. 2003, 10, 95–97., Oral contraceptives combined with interferon β in multiple sclerosis
Carlo Pozzilli, , Laura De Giglio, Valeria T Barletta, Fabiana Marinelli, Floriana De Angelis, Valentina Gallo, Veronica A Pagano, Stefano Marini, Maria C Piattella, Valentina Tomassini, Patrizia Pantano. Oral contraceptives combined with interferon β in multiple sclerosis.Neurol Neuroimmunol Neuroinflamm. 2015 Jun 18;2(4):e120. doi: 10.1212/NXI.0000000000000120
Juliane Klehmet A, , Yvonne Begus-Nahrmann B, Kirsi Taipale C, Gabriele Niemczyk C, Karin Rehberg-Weber. Impact of interferon beta exposure on birth outcome and child development – Results from the post-authorisation safety study PRIMA.Multiple Sclerosis and Related Disorders 77 (2023) 104844
Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.
Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol 2014; 72(Suppl. 1): 39–42.
Langer-Gould A, Smith JB, Albers KB, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 2020; 94: e1939–e1949.
Krysko KM, Rutatangwa A, Graves J, et al. Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis. JAMA Neurol 2020; 77: 327–338.
Begus-Nahrmann Y, Taipale K, Niemczyk G, et al. Interferon beta exposure during pregnancy and breastfeeding: impact on birth outcome and child development – results from the post-authorisation safety study PRIMA. In: 38th congress of the European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS), Amsterdam, The Netherlands, 26–28 October 2022.
Hellwig K, Geissbuehler Y, Sabidó M, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-Beta Pregnancy Registry. J Neurol 2020; 267: 1715–1723.
Hakkarainen KM, Juuti R, Burkill S, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord 2020; 13: 1756286420951072.
P. Cuello, M.L. Martínez Ginés, M.L. Martin Barriga, C. de Andrés. Multiple sclerosis and pregnancy: A single-centre prospective comparative study. DOI: 10.1016/j.nrleng.2014.12.020
Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.
Ladeira F, Salavisa M, Caetano A, et al. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol 2018; 80: 223–227.
Damasceno A, Von Glehn F, Brandão CO, et al. Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci 2013; 324: 29–33.
Bove R, Healy BC, Musallam A, et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler 2016; 22: 935–943.
Graves JS, Henry RG, Cree BAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology 2018; 90: e254–e260
Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520–532.
Westerlind H, Bostrom I, Stawiarz L, et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler 2014; 20: 1578–1583.
Taylor BV, Pearson JF, Clarke G, et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010; 16: 1422–1431.
Trojano M, Lucchese G, Graziano G, et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012; 7: e48078.
Rotstein DL, Chen H, Wilton AS, et al. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology 2018; 90: e1435–e1441.
Magyari M. Role of socio-economic and reproductive factors in the risk of multiple sclerosis. Acta Neurol Scand 2015; 132: 20–23.
Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol 2017; 16: 445–451
Kristen M. Krysko S. Graves2, *, Ruth Dobson3, 4, Ayse Altintas5, Maria Pia Amato6, 7, Jacqueline Berna et al. Sex effects across the lifespan in women with multiple sclerosis Therapeutic Advances in Neurological DisordersVolume 13, 2020 https://doi.org/10.1177/1756286420936166
Ramagopalan SV, Valdar W, Criscuoli M, et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 2009; 16: 342–347.
Sloka JS, Pryse-Phillips WEM, Stefanelli M. The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. Mult Scler 2006; 12: 333–339.
Boesen MS, Magyari M, Koch-Henriksen N, et al. Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977–2015: a nationwide population-based incidence study. Mult Scler 2018; 24: 1077–1086.
Lulu S, Graves J, Waubant E. Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler 2016; 22: 193–200.
Magyari M. Role of socio-economic and reproductive factors in the risk of multiple sclerosis. Acta Neurol Scand 2015; 132: 20–23
Correale J, Arias M, Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1998; 161: 3365–3374.
Soldan SS, Alvarez Retuerto AI, Sicotte NL, et al. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003; 171: 6267–6274.
